Erin Schenk, MD, PhD, discusses the rapidly evolving treatment landscape in lung cancer.
Erin Schenk, MD, PhD, assistant professor of medicine and medical oncology, Division of Medical Oncology, University of Colorado Cancer Center, discusses the rapidly evolving treatment landscape in lung cancer.
The incorporation of pembrolizumab (Keytruda) in the first-line setting of non–small cell lung cancer, in addition to a multitude of immuno-oncology agents in extensive-stage small cell lung cancer, continues to evolve the lung cancer space, says Schenk.
Several studies presented during the 2020 ASCO Virtual Scientific Program have provided the field with a better understanding of how cancer interacts with the immune system and shed light on the importance of clinical trials, Schenk adds.
Moreover, all patients with lung cancer should be considered for clinical trials evaluating biospecimens or new immuno-oncology agents, Schenk concludes.